Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
66. |
ECCT/24/10/05 | Cabotegravir + Rilpivirine Inj A Phase 4, Open-Label, Rollover Study to Provide Continued Access to Cabotegravir Long-acting Injection and Rilpivirine Long-acting Injection to Participants Living with Human Immunodeficiency Virus Type 1 (HIV-1) Infection Who Participated in Long-acting Combination Therapy Studies |
Principal Investigator(s) 1. Abraham Siika Site(s) in Kenya 1. Aga Khan University Hospital Nairobi (Nairobi City county) 2. School of Medicine, College of Health Sciences, Moi University (Uasin Gishu county) 3. Kenya Medical Research Institute-Walter Reed Program (KEMRI-WRP) Clinical Research Site, Kericho (Kericho county) 4. University of Nairobi - Kenyatta National Referral Hospital (Nairobi City county) 5. University of Nairobi - Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county) |
View |
67. |
ECCT/24/10/04 | Cabotegravir + Rilpivirine Inj A Phase 4, Open-Label, Rollover Study to Provide Continued Access to Cabotegravir Long-acting Injection and Rilpivirine Long-acting Injection to Participants Living with Human Immunodeficiency Virus Type 1 (HIV-1) Infection Who Participated in Long-acting Combination Therapy Studies |
Principal Investigator(s) 1. Josphat Kosgei Site(s) in Kenya 1. Kenya Medical Research Institute/Walter Reed Project Clinical Research Centre (Kericho county) 2. School of Medicine, College of Health Sciences, Moi University (Uasin Gishu county) 3. Aga Khan University Hospital Nairobi (Nairobi City county) 4. University of Nairobi - Kenyatta National Referral Hospital (Nairobi City county) 5. University of Nairobi - Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county) |
View |
68. |
ECCT/25/07/05 | Cabotegravir + Rilpivirine Lon A Phase 4, Open-Label, Rollover Study to Provide Continued Access to Cabotegravir Long-acting Injection and Rilpivirine Long-acting Injection to Participants Living with Human Immunodeficiency Virus Type 1 (HIV-1) Infection Who Participated in Longacting Combination Therapy Studie |
Principal Investigator(s) 1. Loice Achieng Ombajo Site(s) in Kenya 1. Aga Khan University Hospital (Nairobi City county) 2. Moi University Clinical Research Centre (Elgeyo/Marakwet county) 3. KEMRI-WRP (Kericho county) 4. University of Nairobi - Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county) |
View |
69. |
ECCT/24/07/02 | TMC278LAHTX4002 A Phase 4, Open-Label, Rollover Study to Provide Continued Access to Cabotegravir Long-acting Injection and Rilpivirine Long-acting Injection to Participants Living with Human Immunodeficiency Virus Type 1 (HIV-1) Infection Who Participated in Longacting Combination Therapy Studies |
Principal Investigator(s) 1. Reena Shah Site(s) in Kenya 1. Aga Khan University Hospital Nairobi (Nairobi City county) 2. School of Medicine, College of Health Sciences, Moi University (Uasin Gishu county) 3. Kenya Medical Research Institute-Walter Reed Program (KEMRI-WRP) Clinical Research Site, Kericho, Kenya (Kericho county) 4. University of Nairobi - Kenyatta National Referral Hospital (Nairobi City county) 5. University of Nairobi - Jaramogi Oginga Odinga Teaching and Referral Hospital (Nairobi City county) |
View |
70. |
ECCT/17/08/01 | A trial to compare the safety and immune response of the normal full and reduced doses of yellow fever vaccines in Kenyan adults A Phase IV randomized, double blinded non-inferiority trial on the immunogenicity and safety of fractional doses of yellow fever vaccines. |
Principal Investigator(s) 1. Philip Bejon Site(s) in Kenya KEMRI Kilifi |
View |